Last edition
News about "BioArctic AB"
Japan Approves Leqembi Pen, a Subcutaneous Formulation
Japan has approved Leqembi Pen, a once-weekly subcutaneous (SC) formulation for early Alzheimer's, offering at-home dosing alongside the intravenous (IV) option.
BioArctic AB | 17/09/2026 | By News Bureau | 111
Eisai Submits EMA Application for Once-Monthly Maintenance Dosing of Alzheimer's Drug Lecanemab
BioArctic partner Eisai has filed a Marketing Authorisation Variation with the EMA seeking approval for a once-every-four-weeks IV maintenance dosing regimen for lecanemab in early Alzheimer’s disease.
BioArctic AB | 27/01/2026 | By News Bureau | 178
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy